公开(公告)号：US09205128B2

公开(公告)日：2015-12-08

申请号：US13637845

申请日：2011-04-01

申请人： Celia Berta Fernandez Ortega ,  Anna Caridys Ramírez Suárez ,  Dionne Casillas Casanova ,  Taimi Emelia Paneque Guerrero ,  Raimundo Ubieta Gómez ,  Marta Dubed Echevarria ,  Leonor Margarita Navea Leyva ,  Lila Rosa Castellanos Serra ,  Carlos Antonio Duarte Cano ,  Viviana Falcón Cama ,  Osvaldo Reyes Acosta

发明人： Celia Berta Fernandez Ortega ,  Anna Caridys Ramírez Suárez ,  Dionne Casillas Casanova ,  Taimi Emelia Paneque Guerrero ,  Raimundo Ubieta Gómez ,  Marta Dubed Echevarria ,  Leonor Margarita Navea Leyva ,  Lila Rosa Castellanos Serra ,  Carlos Antonio Duarte Cano ,  Viviana Falcón Cama ,  Osvaldo Reyes Acosta

IPC分类号： A61K38/10 ,  C12N5/0783 ,  A61K31/713 ,  A61K31/19 ,  A61K38/17 ,  A61K45/06 ,  A61K31/7105 ,  A61K31/5575 ,  C07K14/47 ,  C12N15/113

CPC分类号： A61K38/10 ,  A61K31/19 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/1709 ,  A61K38/1748 ,  A61K45/06 ,  C07K14/47 ,  C07K14/4741 ,  C12N5/0636 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/1132 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31

摘要： The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.

摘要翻译： 本发明描述了通过负面调节或改变细胞骨架，更精确地形成中间细胞骨架细丝的蛋白质来抑制人免疫缺陷病毒（HIV）复制的方法，其中所述蛋白质是波形蛋白和/或角蛋白-10。 通过介入这些蛋白质的结构，人类细胞中病毒的复制被抑制。 本发明还涉及包含肽和/或干扰RNA和/或脂质化合物的试剂的用途，所述试剂产生细胞骨架的负调节或改变以预防或治疗HIV感染。 本发明提供用于改变细胞的细胞骨架/细丝结构的方法和方法，其结果是HIV的人细胞感染被干扰并且甚至可以被完全抑制。 通过减少波形蛋白和/或角蛋白的量（例如通过使用干扰RNA的转录控制）或通过使用破坏细胞骨架的肽来改变细胞骨架。

公开(公告)号：US20130130971A1

公开(公告)日：2013-05-23

申请号：US13637845

申请日：2011-04-01

申请人： Celia Berta Fernandez Ortega ,  Anna Caridys Ramírez Suárez ,  Dionne Casillas Casanova ,  Taimi Emelia Paneque Guerrero ,  Raimundo Ubieta Gómez ,  Marta Dubed Echevarria ,  Leonor Margarita Navea Leyva ,  Lila Rosa Castellanos Serra ,  Carlos Antonio Duarte Cano ,  Viviana Falcón Cama ,  Osvaldo Reyes Acosta

发明人： Celia Berta Fernandez Ortega ,  Anna Caridys Ramírez Suárez ,  Dionne Casillas Casanova ,  Taimi Emelia Paneque Guerrero ,  Raimundo Ubieta Gómez ,  Marta Dubed Echevarria ,  Leonor Margarita Navea Leyva ,  Lila Rosa Castellanos Serra ,  Carlos Antonio Duarte Cano ,  Viviana Falcón Cama ,  Osvaldo Reyes Acosta

IPC分类号： A61K38/10 ,  A61K31/713 ,  A61K31/7105 ,  A61K38/17 ,  A61K45/06 ,  C12N5/0783 ,  A61K31/19

CPC分类号： A61K38/10 ,  A61K31/19 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/1709 ,  A61K38/1748 ,  A61K45/06 ,  C07K14/47 ,  C07K14/4741 ,  C12N5/0636 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/1132 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31

摘要： The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.

摘要翻译： 本发明描述了通过负面调节或改变细胞骨架，更精确地形成中间细胞骨架细丝的蛋白质来抑制人免疫缺陷病毒（HIV）复制的方法，其中所述蛋白质是波形蛋白和/或角蛋白-10。 通过介入这些蛋白质的结构，人类细胞中病毒的复制被抑制。 本发明还涉及包含肽和/或干扰RNA和/或脂质化合物的试剂的用途，所述试剂产生细胞骨架的负调节或改变以预防或治疗HIV感染。 本发明提供用于改变细胞的细胞骨架/细丝结构的方法和方法，其结果是HIV的人细胞感染被干扰并且甚至可以被完全抑制。 通过减少波形蛋白和/或角蛋白的量（例如通过使用干扰RNA的转录控制）或通过使用破坏细胞骨架的肽来改变细胞骨架。

公开(公告)号：US08076297B2

公开(公告)日：2011-12-13

申请号：US11631880

申请日：2005-07-05

申请人： Maria del Carmen Abrahantes Pérez ,  Jesús Reyes González ,  Gloria Véliz Rios ,  Eduardo Martinez Diaz ,  Caridad Anais Gasmuri González ,  José Garcia Suárez ,  Mónica Bequet Romero ,  Luis Javier González López ,  Lila Rosa Castellanos Serra ,  Manuel Selman-Housein Sosa ,  Raúl Gómez Riera ,  Jorge Victor Gavilondo Cowley

发明人： Maria del Carmen Abrahantes Pérez ,  Jesús Reyes González ,  Gloria Véliz Rios ,  Eduardo Martinez Diaz ,  Caridad Anais Gasmuri González ,  José Garcia Suárez ,  Mónica Bequet Romero ,  Luis Javier González López ,  Lila Rosa Castellanos Serra ,  Manuel Selman-Housein Sosa ,  Raúl Gómez Riera ,  Jorge Victor Gavilondo Cowley

IPC分类号： A61K38/43 ,  C12N9/52

CPC分类号： A61K38/16

摘要： The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.

摘要翻译： 本发明涉及能够抑制不同组织起源的肿瘤细胞和活化的内皮细胞的生长的组合物。 所述组合物的组分是对应于来自分子末端的内部甲硫氨酸的对应于C-末端片段的血清素的多肽片段，其可以在它们之间并且任选地与促进组合物的抗肿瘤作用的催乳素蛋白质组合 。 组合物中的生殖细胞可以是0.1-100nM的浓度。 该组合物的抗增殖作用由凋亡机制介导。 “体内”治疗对恶性肿瘤具有抗肿瘤，抗血管生成和保护作用。

公开(公告)号：US08871725B2

公开(公告)日：2014-10-28

申请号：US12280629

申请日：2007-02-28

申请人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodriguez Ulloa ,  Jeovanis Gil Valdés ,  Yassel Ramos Gómez ,  Lila Rosa Castellanos Serra ,  Lázaro Hiram Betancourt Núñez ,  Aniel Sánchez Puente ,  Jorge Fernández de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier González López ,  Vladimir Besada Pérez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

发明人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodriguez Ulloa ,  Jeovanis Gil Valdés ,  Yassel Ramos Gómez ,  Lila Rosa Castellanos Serra ,  Lázaro Hiram Betancourt Núñez ,  Aniel Sánchez Puente ,  Jorge Fernández de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier González López ,  Vladimir Besada Pérez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K38/08 ,  A61K39/00 ,  C07K7/06 ,  A61P35/00 ,  A61K45/06 ,  A61K33/24 ,  A61K31/555

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，mitomicin C，伊马替尼，iressa和velcade（vortezomib）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。

公开(公告)号：US20090130228A1

公开(公告)日：2009-05-21

申请号：US12280629

申请日：2007-02-28

申请人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodriguez Ulloa ,  Jeovanis Gil Valdes ,  Yassel Ramos Gomez ,  Lila Rosa Castellanos Serra ,  Lazaro Hiram Betancourt Nunez ,  Aniel Sanchez Puente ,  Jorge Fernandez de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier Gonzalez Lopez ,  Vladimir Besada Perez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

发明人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodriguez Ulloa ,  Jeovanis Gil Valdes ,  Yassel Ramos Gomez ,  Lila Rosa Castellanos Serra ,  Lazaro Hiram Betancourt Nunez ,  Aniel Sanchez Puente ,  Jorge Fernandez de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier Gonzalez Lopez ,  Vladimir Besada Perez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K33/24 ,  A61K38/08 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/704 ,  A61K31/675 ,  A61K31/407 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/7088 ,  A61P35/00

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，mitomicin C，伊马替尼，iressa和velcade（vortezomib）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。